Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32‐week real‐world experience during the COVID‐19 pandemic
Katharina Hansel, Cataldo Patruno, Elettra Antonelli, Giacomo Dal Bello, Maddalena Napolitano, Gabriella Fabbrocini, Teresa Grieco, Giovanni Pellacani, Maria Concetta Fargnoli, Maria Esposito, Viviana Piras, Myriam Zucca, Giampiero Girolomoni, Luca Stingeni
Abstract
Real‐life data concerning dupilumab effectiveness and safety in adolescents (≥12 to <18 years) with moderate‐to‐severe atopic dermatitis (AD) are rarely reported.1 In the adolescent phase III randomized, placebo‐controlled, clinical trial (LIBERTY AD ADOL)2 and the phase IIa and subsequent phase III open label extension (LIBERTY AD PED‐OLE)3 dupilumab showed significant signs and symptoms improvement at week‐16, with a good safety profile. Herein, we report our real‐life experience on AD adolescents treated with dupilumab.